MarketScreener Homepage > Equities > Euronext Growth Paris > Hybrigenics ALHYG FR0004153930

Real-time Euronext Growth Paris - 03/03 11:35:22 am
0.354	EUR		-11.61%

2018

HYBRIGENICS : Half-year results

2018

HYBRIGENICS : Annual results

2017

HYBRIGENICS : rsquo; compound inhibits Ubiqitin-Specific Protease 10 (USP10) and shows activity in preclinical models of Acute Myeloid Leukemia (AML)

Summary

Quotes 5-day view Real-time Quote.

Real-time Euronext Growth Paris

02/25/2021	02/26/2021	03/01/2021	03/02/2021	03/03/2021	Date
0.282(c)	0.34(c)	0.43(c)	0.4005(c)	0.354(c)	Last
23 706 525	42 116 170	53 233 812	31 577 473	19 041 932	Volume
+9.30%	+20.57%	+26.47%	-6.86%	-11.61%	Change

More quotes

Company

Hybrigenics is a biopharmaceutical company. Hybrigenics and its subsidiaries constitute the DMS Biotech division, which carries the development strategy of DMS (Diagnostic Medical Systems) in the field of biotechnologies, particularly technologies for the treatment of osteoarthritis and regenerative medicine based on the injection of adipose stem cells. Hybrigenics and Servier collaborated on a specific ubiquitin...

Sector

Biotechnology & Medical Research

Calendar

05/03

Earnings Release

More about the company

All news about HYBRIGENICS

2018	HYBRIGENICS : Half-year results	CO
2018	HYBRIGENICS : Annual results	CO
2017	HYBRIGENICS : rsquo; compound inhibits Ubiqitin-Specific Protease 10 (USP10) an..	PU
2017	HYBRIGENICS : Télécharger le document associé Meet Hybrigenics Pharma at SOHO 2..	PU
2017	HYBRIGENICS : gets European patent protection for inhibitors of Ubiquitin-Speci..	PU
2017	HYBRIGENICS : full year 2016 results	PU
2017	HYBRIGENICS : Strategic refocusing on biopharmaceutical R&D	PU
2017	HYBRIGENICS : Encouraging preliminary results of the Phase II clinical study of..	PU
2017	HYBRIGENICS' : patent estate of inhibitors of ubiquitin specific proteases cont..	PU
2016	HYBRIGENICS : rsquo; inecalcitol strengthens key patent protection in the Unite..	PU
2016	HYBRIGENICS : receives green light for a double-blind placebo-controlled Phase ..	PU
2014	HYBRIGENICS : 2014 first-half results and highlights	PU
2014	HYBRIGENICS : successfully raised € 4.6 million	PU
2014	HYBRIGENICS : invests in its genomic capabilities	PU
2014	HYBRIGENICS' : patent estate of inhibitors of ubiquitin-specific proteases is e..	PU

More news

News in other languages on HYBRIGENICS

2020	EN DIRECT DES MARCHES : Unibail, Sodexo, Sanofi, Imerys, Fnac Darty, Solocal, R..
2020	HYBRIGENICS : Comptes et Annexes
2020	HYBRIGENICS : Résultats semestriels 2020
2020	HYBRIGENICS : DMS Biotech participe à l'effort collectif contre le coronavirus
2020	HYBRIGENICS : Développement à Hong Kong avec le partenaire WKK International Li..

More news

Provided by Scoopnest.com

Chart HYBRIGENICS

Duration : Period :

Hybrigenics Technical Analysis Chart | MarketScreener

Full-screen chart

Technical analysis trends HYBRIGENICS

	Short Term	Mid-Term	Long Term
Trends	Bullish	Bullish	Neutral

Technical analysis

Managers and Directors

Name	Title
Julien Gauthier	Chief Executive Officer
Jean-Paul Ansel	Chairman
Jean-François Dufour-Lamartinie	Director-Clinical Research & Development
Philippe Nerin	Independent Director
See-Nuan Simonyi	Director

More about the company

Sector and Competitors

	1st jan.	Capitalization (M$)

HYBRIGENICS	59.10%	100



MODERNA, INC.	40.53%	58 690
LONZA GROUP AG	1.62%	46 935
IQVIA HOLDINGS INC.	6.37%	36 961
CELLTRION, INC.	-15.60%	35 341
SEAGEN INC.	-15.54%	27 847

More Results